IS8332A - Nítróoxýafleiður lósartans, valsartans, kandesartans, telmisartans, eprósartans og ólmesartans sem angíótensín-II viðtakatálmar til að meðhöndla hjarta- og æðasjúkdóma - Google Patents

Nítróoxýafleiður lósartans, valsartans, kandesartans, telmisartans, eprósartans og ólmesartans sem angíótensín-II viðtakatálmar til að meðhöndla hjarta- og æðasjúkdóma

Info

Publication number: IS8332A
Authority: IS; Iceland
Prior art keywords: olmesartan; eprosartan; telmisartan; candesartan; valsartan
Prior art date: 2003-07-31

Application number

IS8332A

Other languages

English (en)

Other versions

IS2534B (is

Inventor

Almirante Nicoletta

Del Soldato Piero

Ongini Ennio

Original Assignee

Nicox S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-31

Filing date

2006-02-27

Publication date

2006-02-27

2006-02-27 Application filed by Nicox S.A. filed Critical Nicox S.A.

2006-02-27 Publication of IS8332A publication Critical patent/IS8332A/is

2009-08-15 Publication of IS2534B publication Critical patent/IS2534B/is

Links

RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 title 2
102000008873 Angiotensin II receptor Human genes 0.000 title 1
108050000824 Angiotensin II receptor Proteins 0.000 title 1
239000002083 C09CA01 - Losartan Substances 0.000 title 1
239000002080 C09CA02 - Eprosartan Substances 0.000 title 1
239000004072 C09CA03 - Valsartan Substances 0.000 title 1
239000002053 C09CA06 - Candesartan Substances 0.000 title 1
239000005537 C09CA07 - Telmisartan Substances 0.000 title 1
208000024172 Cardiovascular disease Diseases 0.000 title 1
239000005480 Olmesartan Substances 0.000 title 1
229960000932 candesartan Drugs 0.000 title 1
SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 title 1
229960004563 eprosartan Drugs 0.000 title 1
OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
229960004773 losartan Drugs 0.000 title 1
125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 title 1
229960005117 olmesartan Drugs 0.000 title 1
VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 title 1
229960005187 telmisartan Drugs 0.000 title 1
229960004699 valsartan Drugs 0.000 title 1
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IS8332A 2003-07-31 2006-02-27 Nítróoxýafleiður lósartans, valsartans, kandesartans, telmisartans, eprósartans og ólmesartans sem angíótensín-II viðtakatálmar til að meðhöndla hjarta- og æðasjúkdóma IS2534B (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP03102379		2003-07-31
PCT/EP2004/051550 WO2005011646A2 (en)	2003-07-31	2004-07-20	Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases

Publications (2)

Publication Number	Publication Date
IS8332A true IS8332A (is)	2006-02-27
IS2534B IS2534B (is)	2009-08-15

Family

ID=34112476

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS8332A IS2534B (is)	2003-07-31	2006-02-27	Nítróoxýafleiður lósartans, valsartans, kandesartans, telmisartans, eprósartans og ólmesartans sem angíótensín-II viðtakatálmar til að meðhöndla hjarta- og æðasjúkdóma

Country Status (29)

Country	Link
US (1)	US20060276523A1 (is)
EP (1)	EP1653950B1 (is)
JP (1)	JP2007500684A (is)
KR (1)	KR20060056352A (is)
CN (1)	CN100496490C (is)
AR (1)	AR045145A1 (is)
AT (1)	ATE383155T1 (is)
AU (1)	AU2004260830B2 (is)
BR (1)	BRPI0413028A (is)
CA (1)	CA2534451A1 (is)
CY (1)	CY1110447T1 (is)
DE (1)	DE602004011230T2 (is)
DK (1)	DK1653950T3 (is)
EC (1)	ECSP066334A (is)
ES (1)	ES2299861T3 (is)
HR (1)	HRP20060084A2 (is)
IL (1)	IL172703A0 (is)
IS (1)	IS2534B (is)
MA (1)	MA27987A1 (is)
MX (1)	MXPA06001263A (is)
NO (1)	NO20060900L (is)
NZ (1)	NZ544463A (is)
PL (2)	PL1653950T3 (is)
PT (1)	PT1653950E (is)
RU (1)	RU2374240C2 (is)
SI (1)	SI1653950T1 (is)
UA (1)	UA87983C2 (is)
WO (1)	WO2005011646A2 (is)
ZA (1)	ZA200600856B (is)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2008506748A (ja)	2004-07-20	2008-03-06	ニコックスエスエイ	ニトロオキシエステル、ニトロオキシチオエステル、ニトロオキシカルボネートおよびニトロオキシチオカルボネートの製造法、該製造法において有用な中間体、ならびにその製造法
WO2006079610A1 (en) *	2005-01-31	2006-08-03	Nicox S.A.	Nitrooxy sartan derivatives as angiotensin ii receptor blockers for the treatment of cardiovascular and inflammatory diseases
RU2306930C1 (ru) *	2005-12-28	2007-09-27	Михаил Владимирович Покровский	Способ коррекции эндотелиальной дисфункции комбинацией лозартана и l-аргинина при l-name-индуцированном дефиците оксида азота
CN101024643A (zh)	2006-02-20	2007-08-29	上海艾力斯医药科技有限公司	咪唑－5－羧酸类衍生物、制备方法及其应用
TW200821303A (en) *	2006-08-08	2008-05-16	Speedel Experimenta Ag	Organic compounds
CA2668744C (en)	2006-11-17	2015-09-15	Queen's University At Kingston	Compounds and methods for treating protein folding disorders
EP2103610B1 (en) *	2006-12-06	2011-09-21	Shanghai Allist Pharmaceutical., Inc.	Salts of imidazol-5-carboxylic acid derivatives, preparation methods and use thereof
TW200831079A (en) *	2006-12-13	2008-08-01	Merck & Co Inc	Angiotensin II receptor antagonists
CA2671421A1 (en) *	2006-12-13	2008-06-26	Merck & Co., Inc.	Nitroderivatives as angiotensin ii receptor antagonists
CN101214242A (zh)	2007-01-05	2008-07-09	上海艾力斯医药科技有限公司	新的药用组合物
EP1980559A1 (en) *	2007-04-10	2008-10-15	CTG Pharma S.r.l.	Cardiovascular agents
CN101317842A (zh)	2007-06-07	2008-12-10	上海艾力斯医药科技有限公司	一种咪唑-5-羧酸衍生物的治疗用途
CN101407511B (zh) *	2007-10-11	2013-01-09	上海艾力斯生物医药有限公司	一种结晶型的咪唑-5-羧酸衍生物
AR069340A1 (es) *	2007-11-26	2010-01-13	Merck & Co Inc	Antagonistas del receptor de angiotensina ii
US9179691B2 (en)	2007-12-14	2015-11-10	Aerodesigns, Inc.	Delivering aerosolizable food products
EP2244575B1 (en) *	2008-01-24	2013-07-17	Merck Sharp & Dohme Corp.	Angiotensin ii receptor antagonists
JP2011511079A (ja)	2008-02-08	2011-04-07	メルク・シャープ・エンド・ドーム・コーポレイション	アンジオテンシンｉｉ受容体アンタゴニスト
WO2009106471A2 (en) *	2008-02-26	2009-09-03	Nicox S.A.	New angiotensin ii receptor blocker derivatives
US20100311800A1 (en) *	2008-02-26	2010-12-09	Nicoletta Almirante	Angiotensin ii receptor antagonists
JP2011523941A (ja) *	2008-05-15	2011-08-25	メルク・シャープ・エンド・ドーム・コーポレイション	アンギオテンシンｉｉ受容体アンタゴニスト
CN101596189A (zh) *	2008-06-05	2009-12-09	上海艾力斯生物医药有限公司	含有咪唑-5-羧酸类衍生物的药用组合物
EP2313417A1 (en) *	2008-06-09	2011-04-27	Nicox S.A.	Angiotensin ii receptor antagonists
AR073259A1 (es) *	2008-07-29	2010-10-28	Merck & Co Inc	Derivados de furosemida utiles como diureticos
WO2010015447A1 (en) *	2008-08-08	2010-02-11	Nicox S.A.	Angiotensin ii receptor antagonists
EP2194048A1 (en)	2008-12-02	2010-06-09	Dirk Sartor	Nitrate esters for the treatment of vascular and metabolic diseases
EP2373630A1 (en)	2008-12-05	2011-10-12	Merck Sharp & Dohme Corp.	Nitrooxy derivatives as angiotensin ii receptor antagonists
SG173044A1 (en)	2009-01-23	2011-08-29	Hanmi Holdings Co Ltd	Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
CA2796710A1 (en)	2010-04-19	2011-10-27	Cardiolynx Ag	Valsartan derivatives carrying nitrogen oxide donors for the treatment of vascular and metabolic diseases
WO2011132171A1 (en) *	2010-04-23	2011-10-27	Piramal Life Sciences Limited	Nitric oxide releasing prodrugs of therapeutic agents
WO2011160974A2 (en)	2010-06-21	2011-12-29	Nicox S.A.	Statin derivatives
JO3350B1 (ar)	2011-03-07	2019-03-13	Merck Sharp & Dohme	مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
WO2014111957A1 (en)	2013-01-21	2014-07-24	Apparao Satyam	Nitric oxide releasing prodrugs of therapeutic agents
CN103275074B (zh) *	2013-06-21	2016-08-10	黄冈鲁班药业股份有限公司	一种奥美沙坦衍生物及其制备方法
CN105820125B (zh) *	2015-01-09	2018-12-07	北京中医药大学	一种用于治疗高血压的化合物及其制备方法和用途
EP3348548A4 (en)	2015-09-07	2019-04-03	Zhejiang Huahai Pharmaceutical Co., Ltd	STAIN OXIDE-RELIEFING PRODRUG MOLECULE
CN106800537B (zh)	2017-01-18	2019-02-01	广东隆赋药业股份有限公司	丁苯酞-替米沙坦杂合物及其制备方法和用途
CN108892624B (zh) *	2018-06-20	2020-12-15	重庆威鹏药业有限公司	沙库巴曲硝基氧衍生物及其制备方法和应用
CN114105881B (zh) *	2020-08-31	2024-01-26	沈阳海诺威医药科技有限公司	血小板聚集抑制剂及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1338238C (en) *	1988-01-07	1996-04-09	David John Carini	Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
EP0403159B1 (en) *	1989-06-14	2000-03-01	Smithkline Beecham Corporation	Imidazolyl-alkenoic acids
RU2067581C1 (ru) *	1989-06-30	1996-10-10	Е.И.Дюпон Де Немур Энд Компани	Аралкилзамещенные имидазолы, обладающие противогипертоническим действием, способ их получения и фармацевтический состав, обладающий ингибирующей активностью в отношении ангиотензина ii
DE69025473T2 (de) *	1989-06-30	1996-10-17	Du Pont	Substituierte imidazole und ihre verwendung als hemmmstoff fur angiotensin ii
AT398202B (de) *	1991-10-04	1994-10-25	Chem Pharm Forsch Gmbh	Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
FR2725987B1 (fr) *	1994-10-19	1997-01-10	Sanofi Sa	Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive
IT1311924B1 (it) *	1999-04-13	2002-03-20	Nicox Sa	Composti farmaceutici.
CA2420055C (en) *	2000-08-25	2010-06-01	Takeda Chemical Industries, Ltd.	Fibrinogen-lowering agent
ITMI20011744A1 (it) *	2001-08-09	2003-02-09	Nicox Sa	Farmaci per le vasculopatie

2004
- 2004-07-20 RU RU2006105804/04A patent/RU2374240C2/ru not_active IP Right Cessation
- 2004-07-20 ES ES04766269T patent/ES2299861T3/es not_active Expired - Lifetime
- 2004-07-20 AU AU2004260830A patent/AU2004260830B2/en not_active Ceased
- 2004-07-20 MX MXPA06001263A patent/MXPA06001263A/es active IP Right Grant
- 2004-07-20 CN CNB200480022483XA patent/CN100496490C/zh not_active Expired - Fee Related
- 2004-07-20 PL PL04766269T patent/PL1653950T3/pl unknown
- 2004-07-20 BR BRPI0413028-6A patent/BRPI0413028A/pt not_active IP Right Cessation
- 2004-07-20 NZ NZ544463A patent/NZ544463A/en unknown
- 2004-07-20 DE DE602004011230T patent/DE602004011230T2/de not_active Expired - Lifetime
- 2004-07-20 DK DK04766269T patent/DK1653950T3/da active
- 2004-07-20 AT AT04766269T patent/ATE383155T1/de not_active IP Right Cessation
- 2004-07-20 US US10/566,292 patent/US20060276523A1/en not_active Abandoned
- 2004-07-20 WO PCT/EP2004/051550 patent/WO2005011646A2/en not_active Ceased
- 2004-07-20 HR HR20060084A patent/HRP20060084A2/hr not_active Application Discontinuation
- 2004-07-20 UA UAA200600273A patent/UA87983C2/ru unknown
- 2004-07-20 KR KR1020067001893A patent/KR20060056352A/ko not_active Ceased
- 2004-07-20 PT PT04766269T patent/PT1653950E/pt unknown
- 2004-07-20 CA CA002534451A patent/CA2534451A1/en not_active Abandoned
- 2004-07-20 JP JP2006521571A patent/JP2007500684A/ja active Pending
- 2004-07-20 SI SI200430655T patent/SI1653950T1/sl unknown
- 2004-07-20 EP EP04766269A patent/EP1653950B1/en not_active Expired - Lifetime
- 2004-07-20 PL PL379420A patent/PL379420A1/pl not_active Application Discontinuation
- 2004-07-28 AR ARP040102685A patent/AR045145A1/es unknown
2005
- 2005-12-20 IL IL172703A patent/IL172703A0/en not_active IP Right Cessation
2006
- 2006-01-30 ZA ZA200600856A patent/ZA200600856B/en unknown
- 2006-01-30 EC EC2006006334A patent/ECSP066334A/es unknown
- 2006-02-13 MA MA28789A patent/MA27987A1/fr unknown
- 2006-02-24 NO NO20060900A patent/NO20060900L/no not_active Application Discontinuation
- 2006-02-27 IS IS8332A patent/IS2534B/is unknown
2008
- 2008-04-07 CY CY20081100385T patent/CY1110447T1/el unknown

Also Published As

Publication number	Publication date
EP1653950B1 (en)	2008-01-09
SI1653950T1 (sl)	2008-06-30
RU2374240C2 (ru)	2009-11-27
AU2004260830B2 (en)	2010-04-29
WO2005011646A2 (en)	2005-02-10
EP1653950A2 (en)	2006-05-10
UA87983C2 (ru)	2009-09-10
AR045145A1 (es)	2005-10-19
CY1110447T1 (el)	2015-04-29
IS2534B (is)	2009-08-15
HRP20060084A2 (hr)	2006-04-30
ATE383155T1 (de)	2008-01-15
DE602004011230D1 (de)	2008-02-21
CN1832742A (zh)	2006-09-13
BRPI0413028A (pt)	2006-10-03
PL1653950T3 (pl)	2008-08-29
ECSP066334A (es)	2006-07-28
DE602004011230T2 (de)	2009-01-02
PT1653950E (pt)	2008-04-11
WO2005011646A3 (en)	2005-04-21
ES2299861T3 (es)	2008-06-01
US20060276523A1 (en)	2006-12-07
KR20060056352A (ko)	2006-05-24
CN100496490C (zh)	2009-06-10
IL172703A0 (en)	2006-04-10
AU2004260830A1 (en)	2005-02-10
JP2007500684A (ja)	2007-01-18
NZ544463A (en)	2009-10-30
CA2534451A1 (en)	2005-02-10
PL379420A1 (pl)	2006-09-04
ZA200600856B (en)	2007-05-30
HK1095093A1 (zh)	2007-04-27
RU2006105804A (ru)	2007-09-20
DK1653950T3 (da)	2008-05-26
NO20060900L (no)	2006-02-24
MA27987A1 (fr)	2006-07-03
MXPA06001263A (es)	2006-04-11

Publication	Publication Date	Title
IS8332A (is)	2006-02-27	Nítróoxýafleiður lósartans, valsartans, kandesartans, telmisartans, eprósartans og ólmesartans sem angíótensín-II viðtakatálmar til að meðhöndla hjarta- og æðasjúkdóma
ZA200810053B (en)	2009-11-25	Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
WO2009058950A3 (en)	2009-07-16	Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
IL181550A0 (en)	2007-07-04	Purification of olmesartan medoxomil
NO20053245D0 (no)	2005-07-01	Tabletter med modifisert frigjoring av bupropionhydroklorid.
GB2454620B (en)	2011-08-17	Solid dosage form of olmesartan medoxomil and amlodipine
IL197934A (en)	2014-01-30	History of hydrobenzamide as hsp90 inhibitors and their use in the treatment of disease
HUS1800044I1 (hu)	2018-12-28	Angiotenzin-II-receptor antagonisták macskák magas vérnyomásának kezelésére
ZA200810474B (en)	2009-09-30	Tablets comprising candesartan cilexetil
ZA200705068B (en)	2008-10-29	Hydantoin derivatives useful as metalloproteinase inhibitors
IL178100A0 (en)	2006-12-31	5-amino-4-hydroxy-7-(1h-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension
EP2036895A4 (en)	2010-12-22	HSP90 INHIBITOR
ZA200800213B (en)	2008-12-31	Benzimidazole derivatives as 5-HT6, 5-HT24
IL176630A0 (en)	2006-10-31	Benzimidazole derivatives
WO2006107062A3 (en)	2006-12-14	Benzimidazole derivative and use as angiotensin ii antagonist
CL2004000379A1 (es)	2005-01-21	Uso de una combinacion farmaceutica de lercanidipina con un bloqueador de los receptores de angiotensina ii, seleccionado de olmesartan, irbesartan, valsartan, telmisartan y losartan, para tratar la hipertension.
IL176140A0 (en)	2006-10-05	Candesartan cilexetil polymorphs
ZA200703495B (en)	2008-10-29	Process for the preparation of irbesartan hydrochloride
EP1778650A4 (en)	2009-12-02	PROCESS OF MANUFACTURING CANDÉSARTAN CILEXÉTIL
WO2006063578A3 (de)	2006-10-12	Verfahren zur herstellung von candesartan
ZA200808598B (en)	2009-12-30	Pyrrolopyrimidine derivatives used as HSP90 inhibitors
ZA200800892B (en)	2009-04-29	Activator of peroxisome proliferator activated receptor δ
UA92485C2 (ru)	2010-11-10	Производная бензамида и ее применение как антагониста ангиотензина ии
GB201018110D0 (en)	2010-12-08	Solid dosage form of olmesartan medoxomil, amiodipine and hydrochlorothiazide
WO2007017469A3 (en)	2007-08-02	Process for preparing an angiotensin ii receptor antagonist